These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 26084637)
1. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Horneff G Expert Opin Drug Saf; 2015 Jul; 14(7):1111-26. PubMed ID: 26084637 [TBL] [Abstract][Full Text] [Related]
2. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry. Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042 [TBL] [Abstract][Full Text] [Related]
3. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144 [TBL] [Abstract][Full Text] [Related]
5. [Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)]. Horneff G Z Rheumatol; 2005 Jun; 64(5):317-26. PubMed ID: 15965816 [TBL] [Abstract][Full Text] [Related]
6. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155 [TBL] [Abstract][Full Text] [Related]
7. Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review. Diener C; Horneff G Expert Opin Drug Saf; 2019 Aug; 18(8):719-732. PubMed ID: 31204508 [No Abstract] [Full Text] [Related]
9. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886 [TBL] [Abstract][Full Text] [Related]
10. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P Rheumatology (Oxford); 2015 Jul; 54(7):1170-6. PubMed ID: 25504896 [TBL] [Abstract][Full Text] [Related]
11. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry. Foeldvari I; Becker I; Horneff G Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824 [TBL] [Abstract][Full Text] [Related]
12. Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Carrasco R; Smith JA; Lovell D Paediatr Drugs; 2004; 6(3):137-46. PubMed ID: 15170361 [TBL] [Abstract][Full Text] [Related]
13. [Autoimmune aspects of treatment with TNF-alpha inhibitors]. Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135 [TBL] [Abstract][Full Text] [Related]
14. New advances in the management of juvenile idiopathic arthritis--2: the era of biologicals. Beresford MW; Baildam EM Arch Dis Child Educ Pract Ed; 2009 Oct; 94(5):151-6. PubMed ID: 19770495 [TBL] [Abstract][Full Text] [Related]
15. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Anink J; Otten MH; Gorter SL; Prince FH; van Rossum MA; van den Berg JM; van Pelt PA; Kamphuis S; Brinkman DM; Swen WA; Swart JF; Wulffraat NM; Dolman KM; Koopman-Keemink Y; Hoppenreijs EP; Armbrust W; ten Cate R; van Suijlekom-Smit LW Rheumatology (Oxford); 2013 Sep; 52(9):1674-9. PubMed ID: 23740187 [TBL] [Abstract][Full Text] [Related]
17. [Biologics for treatment of juvenile idiopathic arthritis. Consensus statement of the 7th Wörlitzer Expertengespräche 2004 for the German Arbeitsgemeinschaft Kinder- und Jugendrheumatologie]. Horneff G Z Rheumatol; 2006 Mar; 65(2):152-6, 158. PubMed ID: 16372138 [TBL] [Abstract][Full Text] [Related]
18. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Ungar WJ; Costa V; Burnett HF; Feldman BM; Laxer RM Semin Arthritis Rheum; 2013 Jun; 42(6):597-618. PubMed ID: 23337074 [TBL] [Abstract][Full Text] [Related]
19. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Machado SH; Xavier RM Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841 [TBL] [Abstract][Full Text] [Related]
20. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. Liu SW; Velez NF; Lam C; Femia A; Granter SR; Townsend HB; Vleugels RA JAMA Dermatol; 2013 Oct; 149(10):1204-8. PubMed ID: 23986394 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]